Uremic inhibitors of erythropoiesis: a study during treatment with recombinant human erythropoietin.
The effects of increasing amounts of uremic sera (US) on the growth of erythroid progenitor cells [burst-forming unit erythroid (BFU-E)] collected from peripheral blood of normal subjects were evaluated to assess the potential role of uremic inhibitors of erythropoiesis during a treatment with recombinant human erythropoietin (r-HuEpo). US were collected from 8 patients on regular dialysis with marked anemia (Hb 6 +/- 0.5 g%) before and after a treatment with high doses of r-HuEpo (from 300 to 525 U/kg/week). Standard cultures for BFU-E were performed in alpha-metylcellulose with fetal calf serum (FCS) and 4 U/ml of r-HuEpo (Cilag, Ortho). In successive cultures, US were added at increasing amounts to the standard culture in order to assess a possible inhibitory effect on BFU-E growth. Finally, in order to assess a possible lack of stimulatory factors, we partially substituted FCS with US. The addition of US collected either before or after therapy with r-HuEpo to the standard culture had no effect on the growth of BFU-E. Vice versa, the number of cultured BFU-E decreased when FCS was partially substituted with US collected before r-HuEpo. This effect was not evident when FCS was partially substituted with US collected after r-HuEpo. No significant differences were recorded in the tested sera collected before and after therapy considering erythropoietin levels and amino acid levels. We hypothesized that some other factors with erythropoietic stimulatory activity (burst-promoting activity?) may be deficient in uremic patients with marked anemia and can be induced during therapy with r-HuEpo.
Brunati
C
C
Divisione di Nefrologia e Dialisi, Niguarda Cà Granda, Milan, Italy.
Cappellini
M D
MD
De Feo
T
T
Guastoni
C
C
Ballerini
L
L
Busnach
G
G
Civati
G
G
Fiorelli
G
G
Minetti
L
L
D000328:Adult; D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D002478:Cells, Cultured; D015672:Erythroid Precursor Cells / Q000502:physiology*; D004920:Erythropoiesis / Q000502:physiology*; D004921:Erythropoietin / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000097:blood / Q000627:therapeutic use*; D006131:Growth Inhibitors / Q000097:blood*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000097:blood; D014511:Uremia / Q000097:blood* / Q000209:etiology
D006131:Growth Inhibitors; D011994:Recombinant Proteins; D004921:Erythropoietin